Gilead debuts new $11M manufacturing control lab in Cork, Ireland

Gilead Sign
Gilead has opened its new $11 million manufacturing facility control lab in Carrigtwohill in Cork, Ireland. (Gilead)

In an effort to boost its production for European, Middle Eastern and Asian markets, Gilead has opened its new $11 million (€9.5 million) manufacturing facility control lab in Carrigtwohill in Cork, Ireland.

The manufacturing site primarily focuses on production of Gilead’s drugs to treat hepatitis and HIV. The company’s newly released HIV drug, Biktarvy, has been taking a bite out of competitor GlaxoSmithKline’s HIV treatments. Gilead’s Cork facility produces about a quarter of the company’s drugs in tablet form, The Irish Times reports.

“We are delighted to launch this significant expansion, which will have a positive impact on the production of vital medicines for hundreds of thousands of patients around the world,” David Cadogan, Gilead’s vice president of manufacturing operations, told The Irish Times. “During the last five years, manufacturing of 11 Gilead products has been transferred to the Carrigtwohill plant, resulting in a significant increase in quality control testing requirements.”

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Both Merck and GE Healthcare also operate manufacturing facilities in Carrigtwohill.

The site was acquired by Gilead from Nycomed in 2007 and has since seen the workforce grow from 60 employees at the plant to 390. The company has said it has invested more than $223 million in the site since the acquisition.

Last week, the company announced plans to locate a new European manufacturing site for its CAR-T therapy Yescarta at the SEGRO Park Amsterdam Airport, and plans on hiring up to 300 employees when the facility is fully operational in 2020.

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.